Skip to main content
SpringerLink
Log in

Supportive oncodermatology—a narrative review of its utility and the way forward

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Supportive oncodermatology is an interdisciplinary field, emerging due to increasing dermatological morbidity in patients with cancer and the recognition of the need for greater collaborative and integrated care to improve patient outcomes. These two unique fields (Oncology and Dermatology) may be integrated in various ways, such as through specialised combined clinics, protocols for expedited access, multidisciplinary groups and meetings, and the development of best practices guidelines. This narrative review consolidates the small but growing literature surrounding supportive oncodermatology; discusses the potential benefit and disadvantages, and areas for future research; and suggests a framework for implementation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

All data and material will be made available.

Code availability

Not applicable

References

  1. Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME (2019) Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatology 155(2):249–251. https://doi.org/10.1001/jamadermatol.2018.4560

    Article  PubMed  Google Scholar 

  2. Giuliani J, Bonetti A (2016) The pharmacological costs for the management of skin toxicity in patients with cancer treated with epidermal growth factor receptor-inhibitors. Clin Lung Cancer 17(6):471–473. https://doi.org/10.1016/j.cllc.2016.04.006

    Article  PubMed  Google Scholar 

  3. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer 16(3):267–273. https://doi.org/10.1007/s00520-007-0318-8

    Article  PubMed  Google Scholar 

  4. Schnur JB, Graff Zivin J, Mattson DMK Jr, Green S, Jandorf LH, Wernicke AG, Montgomery GH (2012) Acute skin toxicity-related, out-of-pocket expenses in patients with breast cancer treated with external beam radiotherapy: a descriptive, exploratory study. Support Care Cancer 20(12):3105–3113. https://doi.org/10.1007/s00520-012-1435-6

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lowe KA, Sangaré L, Bergstresser R, McNamara M, Kafatos G, Garawin T (2019) A national survey of medical oncologist’s opinions and perceptions for managing rash among mCRC patients treated with panitumumab. Dermatol Ther 9(2):337–353. https://doi.org/10.1007/s13555-019-0296-z

    Article  Google Scholar 

  6. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3-4):152–159. https://doi.org/10.1159/000112795

    Article  CAS  PubMed  Google Scholar 

  7. Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, André T, Bensadoun RJ, Bouché O, Ychou M, Dréno B (2013) Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians. J Eur Acad Dermatol Venereol 27(4):419–429. https://doi.org/10.1111/j.1468-3083.2011.04421.x

    Article  CAS  PubMed  Google Scholar 

  8. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14(4):327–333. https://doi.org/10.1007/s40257-013-0021-0

    Article  PubMed  Google Scholar 

  9. Elad S (2019) The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles. Support Care Cancer 27(10):3929–3931. https://doi.org/10.1007/s00520-019-04895-x

    Article  PubMed  Google Scholar 

  10. Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2010) Development of the MASCC Teaching Tool for patients receiving oral agents for cancer. Support Care Cancer 18(5):583–590. https://doi.org/10.1007/s00520-009-0692-5

    Article  PubMed  Google Scholar 

  11. Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugués A, Giacchero D, Romano MC, Riganti J, Lallas K, Peris K, Voudouri D, Lallas A, Fabbrocini G, Lazaridou E, Carrera C, Annunziata MC, Rossi E, Patri A, Rigopoulos D, Stratigos AJ, Apalla Z (2020) Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.08.137

  12. Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K (2021) Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat 185(1):247–253. https://doi.org/10.1007/s10549-020-05914-w

    Article  CAS  PubMed  Google Scholar 

  13. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR (2020) Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center. JAMA Dermatology 156:1079. https://doi.org/10.1001/jamadermatol.2020.1795

    Article  PubMed  Google Scholar 

  14. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/jco.2017.77.6385

    Article  CAS  PubMed  Google Scholar 

  15. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119–iv142. https://doi.org/10.1093/annonc/mdx225

    Article  CAS  PubMed  Google Scholar 

  16. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J ImmunoTherapy Cancer 8(2):e001511. https://doi.org/10.1136/jitc-2020-001511

    Article  Google Scholar 

  17. Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, Seite S, Dreno B (2013) Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res 5:401–408. https://doi.org/10.2147/cmar.s52256

    Article  PubMed  PubMed Central  Google Scholar 

  18. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, Luger T, Triller R, Rougier A, Seité S (2013) Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol 27(9):1071–1080. https://doi.org/10.1111/jdv.12082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lüftner D, Dell'Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre TA, Shenouda G, Romero Fernandez J, Orecchia R, Moyal D, Seité S (2018) Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. Onco Targets Ther 11:5865–5872. https://doi.org/10.2147/ott.s155438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Urakawa R, Tarutani M, Kubota K, Uejima E (2019) Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer 10(20):4846–4851. https://doi.org/10.7150/jca.31059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Borovicka JH, Calahan C, Gandhi M, Abraham TS, Kwasny MJ, Haley AC, West DP, Lacouture ME (2011) Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 147(12):1403–1409. https://doi.org/10.1001/archdermatol.2011.719

    Article  PubMed  Google Scholar 

  22. Nikolaou V, Voudouri D, Tsironis G, Charpidou A, Stamoulis G, Triantafyllopoulou I, Panoutsopoulou I, Xidakis E, Bamias A, Samantas E, Aravantinos G, Gogas H, Rigopoulos D, Syrigos K, Stratigos A (2019) Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. Support Care Cancer 27(12):4535–4542. https://doi.org/10.1007/s00520-019-04751-y

    Article  PubMed  Google Scholar 

  23. Storan ER, McEvoy MT, Wetter DA, el-Azhary RA, Camilleri MJ, Bridges AG, Davis MDP (2015) Experience of a year of adult hospital dermatology consultations. Int J Dermatol 54(10):1150–1156. https://doi.org/10.1111/ijd.12555

    Article  PubMed  Google Scholar 

  24. Koh XQ, Ooi XT, Sun Y, Chandran NS, Tan CL (2020) A retrospective analysis of dermatological problems in haematology and oncology patients at a tertiary Singapore hospital. Australas J Dermatol 61. https://doi.org/10.1111/ajd.13328

  25. Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL (2008) Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113(6):1446–1452. https://doi.org/10.1002/cncr.23714

    Article  PubMed  Google Scholar 

  26. Waddle MR, Kaleem TA, Stross WC, Malouff TD, White L, Li Z, Naessens J, Spaulding A, Aljabri D, Ma DJ, Keole S, Miller RC (2019) Identifying the most costly patients in radiation oncology and predicting the top spenders. J Oncol Pract 15(8):e704–e716. https://doi.org/10.1200/jop.18.00627

    Article  PubMed  Google Scholar 

  27. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357. https://doi.org/10.1200/jco.2008.21.7828

    Article  CAS  PubMed  Google Scholar 

  28. Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol (London, England) 11(4):617–627. https://doi.org/10.2217/fon.14.251

    Article  CAS  Google Scholar 

  29. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94–98. https://doi.org/10.1159/000277656

    Article  CAS  PubMed  Google Scholar 

  30. Tracey EH, Forrestel A, Rosenbach M, Micheletti RG (2016) Inpatient dermatology consultation in patients with hematologic malignancies. J Am Acad Dermatol 75(4):835–836. https://doi.org/10.1016/j.jaad.2016.05.014

    Article  PubMed  Google Scholar 

  31. Galimberti F, Guren L, Fernandez AP, Sood A (2016) Dermatology consultations significantly contribute quality to care of hospitalized patients: a prospective study of dermatology inpatient consults at a tertiary care center. Int J Dermatol 55(10):e547–e551. https://doi.org/10.1111/ijd.13327

    Article  PubMed  Google Scholar 

  32. Song H, Robinson SN, Huang JT (2017) Outpatient dermatology consultation impacts the diagnosis and management of pediatric oncology patients: a retrospective study. J Am Acad Dermatol 77(5):879–885. https://doi.org/10.1016/j.jaad.2017.06.005

    Article  PubMed  Google Scholar 

  33. Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M, Lowe K, Feudjo-Tepie M, Segaert S (2020) Management of EGFR inhibitor-induced skin toxicity and factors impacting patients’ adherence to skin toxicity treatment: health care provider and patient surveys in European oncology centers. Clin Colorectal Cancer 19(2):100–108.e109. https://doi.org/10.1016/j.clcc.2020.01.001

    Article  PubMed  Google Scholar 

  34. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13(13):3913–3921. https://doi.org/10.1158/1078-0432.ccr-06-2610

    Article  CAS  PubMed  Google Scholar 

  35. Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y (2013) Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8(1):e55128. https://doi.org/10.1371/journal.pone.0055128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chen ST, Molina GE, Lo JA, Durbin S, Cohen JV, Reynolds KL, Kroshinsky D (2020) Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol 82(4):994–996. https://doi.org/10.1016/j.jaad.2019.09.026

    Article  CAS  PubMed  Google Scholar 

  37. Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, Rossi AM, Lee EH, Deng L, Markova A, Myskowski PL, Lacouture ME (2020) Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol 34(6):1340–1347. https://doi.org/10.1111/jdv.16159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095. https://doi.org/10.1007/s00520-011-1197-6

    Article  PubMed  PubMed Central  Google Scholar 

  39. Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, Braun M, Fenwick J, Saunders MP (2018) Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol (London, England) 14(24):2531–2541. https://doi.org/10.2217/fon-2018-0187

    Article  CAS  Google Scholar 

  40. Aizman L, Nelson K, Sparks AD, Friedman AJ (2020) The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol 19(5):477–482

    Article  PubMed  Google Scholar 

  41. Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S (2016) Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 175(6):1166–1174. https://doi.org/10.1111/bjd.14756

    Article  CAS  PubMed  Google Scholar 

  42. Prinsen CA, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, Holm EA, Nijsten TE (2013) Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 27(10):1195–1203. https://doi.org/10.1111/jdv.12090

    Article  CAS  PubMed  Google Scholar 

  43. Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR (2013) The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 27(1):e53–e59. https://doi.org/10.1111/j.1468-3083.2012.04466.x

    Article  CAS  PubMed  Google Scholar 

  44. Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y (2018) Targeted therapy-induced facial skin toxicities: impact on quality of life in cancer patients. Asia Pac J Oncol Nurs 5(2):172–177. https://doi.org/10.4103/apjon.apjon_74_17

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chee S-N, Murrell DF (2009) A comparison of Dermatology Life Quality Index scores in a dermatology practice setting. J Am Acad Dermatol 60(3):AB94. https://doi.org/10.1016/j.jaad.2008.11.420

    Article  Google Scholar 

  46. Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G (2019) Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol 25(29):4007–4018. https://doi.org/10.3748/wjg.v25.i29.4007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME (2020) Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.08.005

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, National University Health System, Singapore, Singapore

    Valencia Long

  2. Division of Dermatology, Department of Medicine, National University Health System, Singapore, Singapore

    Ellie Ci-En Choi & Chris Lixian Tan

Authors
  1. Valencia Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellie Ci-En Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Lixian Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Valencia Long: conceptualisation, writing of manuscript, review of literature. Ellie Choi: writing of manuscript, review of literature, editing of manuscript. Chris Tan: review of manuscript.

Corresponding author

Correspondence to Valencia Long.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

No ethics approval was required for this manuscript.

Consent to participate

Not applicable

Consent for publication

All authors consent to publication.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Long, V., Choi, E.CE. & Tan, C.L. Supportive oncodermatology—a narrative review of its utility and the way forward. Support Care Cancer 29, 4931–4937 (2021). https://doi.org/10.1007/s00520-021-06124-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-021-06124-w

Keywords

Search

Navigation